Study and Modulation of Immune Responses in Primary and Metastatic Colon Cancers

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · May 26, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how the immune system interacts with colon cancer, specifically both primary and metastatic (spread) forms of the disease. Researchers believe that the immune response plays a significant role in how these cancers develop and progress. By studying these immune responses, the aim is to find new ways to treat or prevent cancer recurrences, especially since current treatments, like chemotherapy and immunotherapy, only work for some patients.

To participate in this study, individuals must be 18 years or older and diagnosed with colorectal adenocarcinoma, which is a type of colon cancer. They should also be scheduled for surgery to remove the tumor or any metastatic sites. However, certain people, such as those who cannot comprehend the study information or are involved in the research process, will not be eligible. Participants can expect to contribute to important research that could help improve treatment options for colon cancer in the future, and their involvement will last for about five years.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female 18 years of age or older
• • Diagnosis of colorectal adenocarcinoma
• • Scheduled resection of tumor and/or metastasis(es)
• Exclusion Criteria:
• • Patient's opposition to research
• • Patients under guardianship
• • The following situations
• • 1. Persons unable to understand and/or read the information leaflet
• • 2. Patient with one of the following functions: Investigator or co-investigator, research assistant, pharmacist, study coordinator or, having any involvement in the study
• • 3. Non-cooperative or potentially non-compliant person for the study and its procedures with foreseeable difficulties in regular follow-up over 5 years.
• • 4. Non-affiliation with a social security scheme, Couverture Médicale Universelle or any equivalent scheme.
• • Pregnant or breast-feeding women.
• • HIV-positive patients.